DURECT (NASDAQ:DRRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRXGet Rating) in a research note issued to investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Zacks Investment Research downgraded DURECT from a “hold” rating to a “sell” rating in a research note on Thursday, May 5th.

Shares of NASDAQ DRRX opened at $0.40 on Friday. DURECT has a one year low of $0.37 and a one year high of $1.85. The company has a current ratio of 7.83, a quick ratio of 7.60 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $91.17 million, a PE ratio of -2.50 and a beta of 1.47. The business has a 50-day moving average price of $0.53 and a two-hundred day moving average price of $0.77.

DURECT (NASDAQ:DRRXGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). DURECT had a negative net margin of 270.27% and a negative return on equity of 60.89%. During the same period in the prior year, the firm earned ($0.05) EPS. Research analysts anticipate that DURECT will post -0.19 EPS for the current year.

In related news, Director Judith J. Robertson acquired 200,000 shares of the company’s stock in a transaction on Monday, March 14th. The stock was purchased at an average cost of $0.59 per share, for a total transaction of $118,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 236,700 shares of company stock valued at $132,505 over the last quarter. Corporate insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Lion Point Capital LP increased its position in DURECT by 1.2% in the 3rd quarter. Lion Point Capital LP now owns 15,486,004 shares of the specialty pharmaceutical company’s stock valued at $19,822,000 after acquiring an additional 177,435 shares in the last quarter. BlackRock Inc. increased its position in DURECT by 0.3% in the 3rd quarter. BlackRock Inc. now owns 14,341,444 shares of the specialty pharmaceutical company’s stock valued at $18,357,000 after acquiring an additional 39,239 shares in the last quarter. Geode Capital Management LLC increased its position in DURECT by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,873,448 shares of the specialty pharmaceutical company’s stock valued at $4,958,000 after acquiring an additional 126,212 shares in the last quarter. CM Management LLC increased its position in DURECT by 20.9% in the 1st quarter. CM Management LLC now owns 3,535,732 shares of the specialty pharmaceutical company’s stock valued at $2,369,000 after acquiring an additional 610,537 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in DURECT by 20.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,500,278 shares of the specialty pharmaceutical company’s stock valued at $2,345,000 after acquiring an additional 588,848 shares in the last quarter. 50.60% of the stock is currently owned by institutional investors and hedge funds.

About DURECT (Get Rating)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

See Also

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.